Our discussion will cover the scientific mechanisms at play, the symptoms to be aware of, diagnostic approaches, and the various management strategies available
In STEP 1 [1] , the largest trial with 1,961 participants [1] , patients receiving semaglutide 2.4 mg weekly achieved an average weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021)
doi: 10.7759/cureus.49926, 79
During dose escalation in the clinical trials, subjects were allowed to remain at a GLP1 dose for up to 8 weeks, as needed, to allow GI side effects to dissipate [14, 15]
In a 2021 retrospective study, Lee and Padgett compared the effectiveness of knee injections using BPC- 157 alone to knee injections using a combination of BPC-157 and thymosin-beta-4 (TB4), which is another peptide shown to have anti-inflammatory properties